| dc.contributor |
University of Michigan Medical Center, Ann Arbor, MI, USA |
|
| dc.contributor |
University of Kansas Medical Center, Kansas City, KS, USA |
|
| dc.contributor |
Southwest Oncology Group Statistical Center, Seattle, WA, USA |
|
| dc.contributor |
University of Colorado, Denver, CO, USA |
|
| dc.contributor |
Columbus Oncology Associates, Columbus, OH, USA |
|
| dc.contributor |
University of Kansas Medical Center, Kansas City, KS, USA |
|
| dc.contributor |
Ann Arbor |
|
| dc.creator |
Allen, Ace |
|
| dc.creator |
Wolf, Michael |
|
| dc.creator |
Crawford, E. David |
|
| dc.creator |
Davis, Mellar P. |
|
| dc.creator |
Natale, Ronald B. |
|
| dc.creator |
Barnett, Margaret L. |
|
| dc.date |
2006-09-11T15:43:12Z |
|
| dc.date |
2006-09-11T15:43:12Z |
|
| dc.date |
1992-06 |
|
| dc.date.accessioned |
2022-05-19T13:30:45Z |
|
| dc.date.available |
2022-05-19T13:30:45Z |
|
| dc.identifier |
Allen, Ace; Wolf, Michael; Crawford, E. David; Davis, Mellar P.; Natale, Ronald B.; Barnett, Margaret L.; (1992). "Phase II evaluation of piroxantrone in renal cell carcinoma." Investigational New Drugs 10(2): 129-132. <http://hdl.handle.net/2027.42/45142> |
|
| dc.identifier |
0167-6997 |
|
| dc.identifier |
1573-0646 |
|
| dc.identifier |
http://hdl.handle.net/2027.42/45142 |
|
| dc.identifier |
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1500267&dopt=citation |
|
| dc.identifier |
1500267 |
|
| dc.identifier |
http://dx.doi.org/10.1007/BF00873131 |
|
| dc.identifier |
Investigational New Drugs |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/117389 |
|
| dc.description |
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m 2 q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were no partial nor complete responses. There were two mixed responses. Significant white cell toxicity, anemia, nausea, and vomiting were observed. Mild or moderate degrees of fever, malaise, and stomatitis occurred. No significant cardiac toxicity was noted. Piroxantrone does not have significant activity as a single agent in advanced renal cell carcinoma. |
|
| dc.description |
Peer Reviewed |
|
| dc.description |
http://deepblue.lib.umich.edu/bitstream/2027.42/45142/1/10637_2004_Article_BF00873131.pdf |
|
| dc.format |
268963 bytes |
|
| dc.format |
3115 bytes |
|
| dc.format |
application/pdf |
|
| dc.format |
text/plain |
|
| dc.format |
application/pdf |
|
| dc.language |
en_US |
|
| dc.publisher |
Kluwer Academic Publishers; Springer Science+Business Media |
|
| dc.subject |
Medicine & Public Health |
|
| dc.subject |
Pharmacology/Toxicology |
|
| dc.subject |
Oncology |
|
| dc.subject |
Piroxantrone |
|
| dc.subject |
Renal Cell Carcinoma |
|
| dc.subject |
Chemical Engineering |
|
| dc.subject |
Radiology |
|
| dc.subject |
Chemistry |
|
| dc.subject |
Biological Chemistry |
|
| dc.subject |
Science |
|
| dc.subject |
Health Sciences |
|
| dc.subject |
Engineering |
|
| dc.title |
Phase II evaluation of piroxantrone in renal cell carcinoma |
|
| dc.type |
Article |
|